1
|
Jonville-Bera AP, Gautier S, Micallef J, Massy N, Atzenhoffer M, Grandvuillemin A, Drici MD. Monitoring the safety of drugs and COVID-19 vaccines by the French Pharmacovigilance Centers during the pandemic: A win-win bet with Health Authorities! Therapie 2023; 78:467-475. [PMID: 37012154 PMCID: PMC9990876 DOI: 10.1016/j.therap.2023.03.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2023] [Accepted: 02/28/2023] [Indexed: 03/09/2023]
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) pandemic virus was a "health crisis" and a significant burden also for the French pharmacovigilance system. It took its toll in 2 phases, the first being in early 2020 when very little was known, and during which the missions of the 31 Regional Pharmacovigilance Centers (RPVCs) from university hospitals were to detect adverse reactions of drugs used in the context of the disease. Whether as a possible aggravating role on COVID-19, or displaying a different safety profile during its course, or to assess safety of curative treatment, this phase preceded that of the arrival of dedicated vaccines. Then the RPVCs' missions were to detect, as early as possible, any new serious adverse effect leading to a potential signal that would modify the benefit/risk ratio of a vaccine and require the implementation of health safety measures. During these two distinct periods, signal detection remained the core business of the RPVCs. Each RPVC had to organize itself to handle an unprecedented surge of declarations and requests for advice, from health care professionals and patients alike. "Leading" RPVCs, who were in charge of monitoring vaccines, had to deal with an extraordinary workload (still going on to this date), to generate in real-time and on a weekly basis, a summary of all the adverse drug reaction (ADR) reports as well as an extended analysis of the different safety signals. The organization put in place at the beginning of the health crisis, adapted to the context of the vaccines, allowed to meet the challenge of real-time pharmacovigilance monitoring, and to identify many safety signals. Efficient "short-circuits exchanges" with the French Regional Pharmacovigilance Centers Network (RPVCN) were paramount to the National Agency for the Safety of Medicines and Health Products (ANSM) to develop an optimal collaborative partnership. The French RPVCN has shown at this occasion both agility and flexibility, swiftly adapting to vaccine- and media-related unrest, and demonstrated its effectiveness in the early detection of safety signals. This crisis also confirmed the superiority of manual/human signal detection over automated ones, as the most effective and powerful tool to date to rapidly detect and validate a new ADR and enable to elaborate rapid risk reduction measures. To maintain the performance of French RPVCN in signal detection and to monitor all drugs as they should, and as expected by our fellow citizens, a new funding model should be considered.
Collapse
Affiliation(s)
- Annie Pierre Jonville-Bera
- Service de pharmacosurveillance, centre régional de pharmacovigilance, centre Val de Loire, CHRU de Tours, 37000 Tours, France.
| | - Sophie Gautier
- Service de pharmacologie, centre régional de pharmacovigilance Nord Pas de Calais, CHRU de Lille, 59000 Lille, France
| | - Joëlle Micallef
- Service de pharmacologie, centre régional de pharmacovigilance, et université d'Aix Marseille, APHM, INSERM, Inst Neurosci Syst, UMR 1106, 13005 Marseille, France
| | - Nathalie Massy
- Service de pharmacologie médicale, centre régional de pharmacovigilance de Rouen, CHRU de Rouen, 76000 Rouen, France
| | - Marina Atzenhoffer
- Centre régional de pharmacovigilance, hospices civils de Lyon, 69000 Lyon, France
| | - Aurélie Grandvuillemin
- Service de pharmacologie, centre régional de pharmacovigilance de Nice, CHRU de Nice, 06000 Nice, France
| | - Milou-Daniel Drici
- Centre régional de pharmacovigilance de Bourgogne, CHRU de Dijon, 21000 Dijon, France
| |
Collapse
|
2
|
Jonville-Bera AP, Gautier S, Micallef J, Massy N, Atzenhoffer M, Drici MD, Grandvuillemin A. [Monitoring the safety of drugs and COVID-19 vaccines by the French Pharmacovigilance Centers during the pandemic: a win-win bet with Health Authorities!]. Therapie 2023; 78:477-488. [PMID: 36890032 PMCID: PMC9943552 DOI: 10.1016/j.therap.2023.02.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2023] [Accepted: 02/21/2023] [Indexed: 02/23/2023]
Abstract
The pandemic subsequent to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus resulted, for the French institutional pharmacovigilance, in a "health crisis" in 2 phases: the coronavirus disease 2019 - "COVID-19" phase during which the missions of the Regional Pharmacovigilance Centres (RPVC) were to detect a possible impact of drugs on this disease, as whether existed a possible aggravating role of certain drugs, or the safety profile of drugs used for the management of COVID-19 could evolve. The second phase followed the availability of COVID-19 vaccines, during which the RPVCs' missions were to detect as early as possible any new serious adverse effect, source of a potential signal that would modify the benefit/risk ratio of a vaccine and require the implementation of health safety measures. During these two periods, signal detection remained the core business of the RPVCs. The RPVCs had to organize themselves to handle an historical surge of declarations and requests for advice, whereas the RPVCs in charge of monitoring vaccines had to deal with an extraordinary dense activity over a long period of time, in order to produce in real time and on a weekly basis, a summary of all the declarations and an analysis of safety signals. The national organization put in place made it possible to meet the challenge of real-time pharmacovigilance monitoring of 4 vaccines with conditional marketing authorizations. Short-circuit efficient exchanges with the French Regional Pharmacovigilance Centres Network was paramount for the French National Agency for medicines and health products (Agence nationale de sécurité du médicament et des produits de santé) to develop an optimal collaborative partnership. The RPVC network has shown agility and flexibility, has been able to adapt swiftly and demonstrated its effectiveness in the early detection of safety signals. This crisis confirmed the superiority of manual/human signal detection as the most effective and powerful tool to date, to rapidly detect a new adverse drug reaction and enable to elaborate rapid measures of risk reduction. In order to maintain the performance of French RPVCs in signal detection and to monitor all drugs as they should and as expected by our fellow citizens, a new funding model correcting the inadequacy of RPVCs' expertise resources in relation to the volume of reports should be considered.
Collapse
Affiliation(s)
- Annie Pierre Jonville-Bera
- Service de pharmacosurveillance, centre régional de pharmacovigilance Centre Val de Loire, CHRU de Tours, 37000 Tours, France.
| | - Sophie Gautier
- Service de pharmacologie, centre régional de pharmacovigilance Nord Pas de Calais, CHRU de Lille, 59000 Lille, France
| | - Joëlle Micallef
- Inserm, service de pharmacologie, université d'Aix-Marseille, UMR 1106, APHM, centre régional de pharmacovigilance, institut de neuroscience des systèmes, 13005 Marseille, France
| | - Nathalie Massy
- Service de pharmacologie médicale, centre régional de pharmacovigilance de Rouen, CHRU de Rouen, 76000 Rouen, France
| | - Marina Atzenhoffer
- Centre régional de pharmacovigilance, hospices civils de Lyon, 69000 Lyon, France
| | - Milou-Daniel Drici
- Service de pharmacologie, centre régional de pharmacovigilance de Nice, CHRU de Nice, 06000 Nice, France
| | | |
Collapse
|
3
|
Bekal S, Husari G, Okura M, Huang CA, Bukari MS. Thrombosis Development After mRNA COVID-19 Vaccine Administration: A Case Series. Cureus 2023; 15:e41371. [PMID: 37546104 PMCID: PMC10400017 DOI: 10.7759/cureus.41371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/04/2023] [Indexed: 08/08/2023] Open
Abstract
The coronavirus disease 2019 (COVID-19) pandemic remains one of the largest global health crises of the last century. Fortunately, COVID-19 vaccines have proven to be one of the most promising options in halting the progression of the pandemic. As more and more people receive COVID-19 vaccines, the medical community has learned a great deal about their efficacy and the occurrence of very rare adverse effects. While the number of thromboembolic events post-adenoviral vaccines has been well-documented in the medical literature, there has been limited information regarding thrombosis development after receiving a messenger RNA (mRNA)-based vaccine. This case series highlights four different patients who received an mRNA-based COVID-19 vaccine and subsequently developed venous thromboembolism. Therefore, we hope that after reviewing this article, physicians will be more aware of thrombosis-related developments following mRNA vaccine administration for COVID-19. Fortunately, with early diagnosis and prompt treatment, patients can still expect full recovery from any vaccine thrombosis-associated complications, and the benefits of receiving an mRNA-based COVID-19 vaccine still outweigh the risks of post-vaccination complications.
Collapse
Affiliation(s)
- Sundeep Bekal
- Internal Medicine, Community Hospitalist Physician Group, Fresno, USA
| | - George Husari
- Internal Medicine, University of California, San Francisco Fresno, Fresno, USA
| | - Marcel Okura
- Internal Medicine, University of California, San Francisco Fresno, Fresno, USA
| | - Charity A Huang
- Hematology and Oncology, Harbor-University of California Los Angeles Medical Center, Torrance, USA
| | - Mohammed S Bukari
- Hematology and Oncology, University of California, San Francisco Fresno, Fresno, USA
| |
Collapse
|
4
|
Coca JR, Coca-Asensio R, Esteban Bueno G. Socio-historical analysis of the social importance of pharmacovigilance. FRONTIERS IN SOCIOLOGY 2022; 7:974090. [PMID: 36505765 PMCID: PMC9732674 DOI: 10.3389/fsoc.2022.974090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/20/2022] [Accepted: 11/15/2022] [Indexed: 06/17/2023]
Abstract
Pharmacovigilance is a scientific discipline that has changed a lot in recent years and is of great social importance. The case of the so-called sulfonamide elixir showed society the importance of this discipline. Since then, pharmacovigilance has evolved into a scientific discipline with a strong social character. In this paper, a historical review is made of several paradigmatic examples of this discipline to reflect on what pharmacovigilance could be like finally. We conclude that this discipline could be more closely related to other areas of the social sciences, which would help to promote a more democratic social environment taking into account the needs of individuals and social groups.
Collapse
Affiliation(s)
- Juan R. Coca
- Unit for Social Research in Health and Rare Diseases, Faculty of Education of Soria, University of Valladolid, Soria, Spain
| | - Raquel Coca-Asensio
- Department of Neurosciences (Pharmacology), University of Cadiz, Cadiz, Spain
| | - Gema Esteban Bueno
- Almeria Periphery Clinical Management Unit, Almería Health District, Andalusian Health Service, Almeria, Spain
| |
Collapse
|
5
|
Ghrieb Z, Salmona M, Michonneau D, De Saisset C, Allaoua S, Kiladjian JJ, Le Goff J, Bergeron A, Benajiba L. Impact of the COVID-19 pandemic on antiviral drug development for other community-acquired respiratory viruses’ infections. Therapie 2022; 78:241-245. [PMID: 36030128 PMCID: PMC9341168 DOI: 10.1016/j.therap.2022.07.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2022] [Revised: 07/19/2022] [Accepted: 07/28/2022] [Indexed: 12/05/2022]
Abstract
The coronavirus disease 2019 (COVID-19) pandemic indirectly resulted in missed therapeutic opportunities for many diseases. Here we focus on community-acquired respiratory viruses other than severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) [respiratory syncytial virus, parainfluenza and influenza A], and highlight the pandemics impact on clinical trials to develop novel therapies for other severe respiratory viral infections. We retrospectively reviewed inclusion rates within respiratory antiviral clinical trials in comparison with all other clinical trials in our clinical investigations center, before and during the COVID-19 pandemic. As opposed to the remaining clinical trials developed within our unit, respiratory antiviral trials inclusion rates did not recover after the initial recruitment decrease observed across all trials during the first pandemic wave. These results were discussed in the context of non-COVID-19 respiratory viral infection rates within our center, showing a general decline in seasonal respiratory viruses spread since the COVID-19 pandemic onset. Virus epidemiology changes upon the wide SARS-CoV-2 expansion as well as the lifestyle changes globally adopted to prevent SARS-CoV-2 transmission could have therefore contributed to the negative impact of the COVID-19 pandemic on antiviral drug development. Our study highlights the peculiarity of respiratory antiviral drug development during the COVID-19 pandemic era and describes potential explanations for such drug development halting.
Collapse
|
6
|
Bakhshwin D, Alotaibi M, Ali AS, Althomali A, Alsuwat A, Alhamyani A, Alwathnani A, Alsaggaf S, Alrafiah A. Mortality Predictors Among COVID-19 Elderly in Taif, Saudi Arabia. Infect Drug Resist 2022; 15:3213-3223. [PMID: 35754783 PMCID: PMC9231416 DOI: 10.2147/idr.s364279] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2022] [Accepted: 06/09/2022] [Indexed: 11/23/2022] Open
Abstract
Background By December 2021, the COVID-19 pandemic had caused more than 266 million cases and 5 million deaths, especially among geriatric patients. Objective To identify determinants of COVID-19-related death in geriatric patients. Methods This is a comparative retrospective study involving 145 COVID-19 hospitalized patients who are more than 60 years old, conducted at King Faisal Medical Complex in Taif, Saudi Arabia, from June 2020 to August 2020. The main outcome studied was COVID-19-related death. Results Out of 145 elderly COVID-19 patients, 11% have died. There was a significant difference between those who died and the surviving group regarding hospital stay duration, with a higher duration median among those who died (22 days vs 12 day respectively, p=0.002). Transfer to ICU, mechanical ventilation, low oxygen saturation, shortness of breath, respiratory support, x-ray trend, and prolonged QT interval showed significant statistical differences between them (p<0.001, <0.001, 0.017, 0.045, <0.001, <0.001, 0.004, respectively). After doing logistic regression of predictors for progression to death, putting patients on oxygen only vs mechanical ventilation was statistically significant, with an adjusted odds ratio (AOR) of 0.038 (p=0.012). Worse x-rays vs constant also were statistically significant and had AOR of 23.459 (p=0.001). There was a significant moderate positive correlation between duration of hospital stay and duration from admission to medication start (SP=0.336 and p<0.001). Conclusion We recommend accurately monitoring patients using x-rays to determine which patients have worse x-rays. However, the cost-benefit of using radiation must be well assessed and needs further research to determine if its benefit outweighs its risks, especially in high-risk patients. Furthermore, mechanically ventilated patients must be carefully monitored. Finally, the duration of hospital stay was highly correlated with the duration from admission to medication start. Therefore, proper treatment must be started as early as possible.
Collapse
Affiliation(s)
- Duaa Bakhshwin
- Department of Pharmacology Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia
| | - Musim Alotaibi
- King Faisal Medical Complex, Taif, Kingdom of Saudi Arabia
| | - Ahmed S Ali
- Department of Pharmacology Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.,Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut, Egypt
| | | | | | | | | | - Samar Alsaggaf
- Department of Anatomy, Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia
| | - Aziza Alrafiah
- Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia
| |
Collapse
|
7
|
Montastruc J, Biron P, Sommet A. NVX‐Cov2373 Novavax Covid‐19 vaccine: A further analysis of its efficacy using multiple modes of expression. Fundam Clin Pharmacol 2022; 36:1125-1127. [PMID: 35502459 PMCID: PMC9348229 DOI: 10.1111/fcp.12794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2022] [Revised: 03/28/2022] [Accepted: 05/02/2022] [Indexed: 11/27/2022]
Abstract
A fifth vaccine against Covid‐19, NVX‐CoV2373 Nuvavoxid® (Novavax), a protein‐based adjuvanted vaccine, was recently marketed in Europe. The main clinical trial before marketing concluded to a ‘vaccine efficacy’ of 89.7% without talking about other validated efficacy parameters. We further analysed the data of this clinical trial using the different validated methods of risk expression: absolute risks (AR), AR reduction (ARR) and number needed to treat (NNT). ARR and NNT values were 1.22% and 82, respectively, for an RR value of 0.10. Description of these parameters allowed defining some interesting characteristics of NVX‐CoV2373 efficacy according to age, race, variant and coexisting illness. Finally, we ask that the results of clinical trials be systematically presented, using not only RR but also including AR, ARR and NNT.
Collapse
Affiliation(s)
- Jean‐Louis Montastruc
- Service de Pharmacologie Médicale et Clinique, CIC INSERM 1436, Faculté de Médecine Centre Hospitalier Universitaire Toulouse France
| | - Pierre Biron
- Pharmacologie Médicale, Faculté de Médecine Université de Montréal Montreal Quebec Canada
| | - Agnès Sommet
- Service de Pharmacologie Médicale et Clinique, CIC INSERM 1436, Faculté de Médecine Centre Hospitalier Universitaire Toulouse France
| |
Collapse
|
8
|
Yousaf Z, Ata F, Mohammed Hammamy RA. Thrombosis post-mRNA-based SARS-CoV-2 vaccination (BNT162b2) - Time to think beyond thrombosis with thrombocytopenia syndrome (TTS). THROMBOSIS UPDATE 2022; 7:100104. [PMID: 38620755 PMCID: PMC9013693 DOI: 10.1016/j.tru.2022.100104] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2022] [Revised: 03/20/2022] [Accepted: 04/04/2022] [Indexed: 11/27/2022] Open
Abstract
The COVID-19 pandemic has affected the global socioeconomic and healthcare infrastructure. Vaccines have been the cornerstone in limiting the global spread of the pandemic. However, the mass scale vaccination has resulted in some unanticipated adverse events. Arguably the most serious of these has been the development of widespread thrombosis with viral-vectored vaccines. We present a case of extensive thrombosis associated with the messenger RNA (m-RNA) vaccine.
Collapse
Affiliation(s)
- Zohaib Yousaf
- Department of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar
| | - Fateen Ata
- Department of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar
| | | |
Collapse
|
9
|
Schultz É, Atlani-Duault L, Peretti-Watel P, Ward JK. Does the public know when a scientific controversy is over? Public perceptions of hydroxychloroquine in France between April 2020 and June 2021. Therapie 2022; 77:591-602. [PMID: 35101281 PMCID: PMC8801974 DOI: 10.1016/j.therap.2022.01.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Revised: 12/29/2021] [Accepted: 01/10/2022] [Indexed: 11/24/2022]
Abstract
Objectives In the early stages of the coronavirus disease 2019 (COVID-19) pandemic, chloroquine and its derivatives such as hydroxychloroquine (HCQ) were widely commented upon both within the scientific community and in the media. This paper explores the different factors that influenced public perceptions in France of the efficacy of HCQ as well as their evolution between April 2020 and June 2021. Methods This article draws on 5 surveys conducted among representative samples of the French population (projects COCONEL and TRACTRUST; quota method, n = 1006; 1004; 2006; 1014 and 1005). We asked questions on the effectiveness of chloroquine against COVID-19. We also collected sociodemographic variables and attitudes toward politics and science. Results Between April and June 2021, the proportion of respondents who believed in the efficacy of HCQ decreased rapidly from 35% to 14%. The proportion of respondents who believed that HCQ is ineffective rose gradually from 6% to 21%. After adjusting for the temporal effect, the logistic regression showed a very strong association between political orientation and the belief in the efficacy of HCQ. Respondents who felt closest to the more radical parties (far-right and far-left) were more likely to believe in the efficacy of HCQ than those who felt closest to the political center (O.R. 2.48 [1.95–3.15] and 1.87 [1.44–2.43]). The role of trust in the government and in science and of the degree of political engagement were investigated in the two waves conducted after the scientific consensus was established during the summer of 2020. High levels of trust in the government and in science and of politicization are associated with belief of HCQ proven inefficacy. Across the whole period, a majority of respondents were uncertain. Even in 2021, 41.5% stated that the data were insufficient to decide whether or not HCQ is effective and 25.2% stating that they did not know. Conclusion Because media coverage of scientific controversies is higher in times of uncertainty than after these controversies have died down, the publicization of therapeutic promises can have lasting consequences on attitudes towards science and medicine.
Collapse
Affiliation(s)
- Émilien Schultz
- Université de Paris, IRD, Inserm, CEPED (UMR 196), 75006 Paris, France; Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Equipe CANBIOS Labellisée Ligue Contre le Cancer, 13005 Marseille, France.
| | - Laëtitia Atlani-Duault
- Université de Paris, IRD, Inserm, CEPED (UMR 196), 75006 Paris, France; Institut COVID-19 Add Memoriam, université de Paris, 75006 Paris, France; WHO Collaborative Center for Research on Health and Humanitarian Policies and Practices, IRD, université de Paris, 75006 Paris, France; Columbia University, Mailman School of Public Health, New York, NY, USA
| | - Patrick Peretti-Watel
- VITROME, Aix-Marseille université, IRD, AP-HM, SSA, 13005 Marseille, France; Observatoire régional de la santé PACA (ORS Paca), Aix-Marseille université, 13385 Marseille, France
| | - Jeremy K Ward
- VITROME, Aix-Marseille université, IRD, AP-HM, SSA, 13005 Marseille, France; CERMES3, Inserm, CNRS, EHESS, université de Paris, 94801 Villejuif, France
| |
Collapse
|
10
|
Schultz É, Mignot L, Ward JK, Boaventura Bomfim D, Chabannon C, Mancini J. Public perceptions of the association between drug effectiveness and drug novelty in France during the COVID-19 pandemic. Therapie 2022; 77:693-701. [PMID: 35599194 PMCID: PMC9077798 DOI: 10.1016/j.therap.2022.05.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2022] [Revised: 04/11/2022] [Accepted: 05/02/2022] [Indexed: 12/16/2022]
Abstract
OBJECTIVES During the coronavirus disease 2019 (COVID-19) pandemic, public debates overtly addressed the promises of new innovative drugs. Many of these debates pitted those who advocated for the development of new drugs by pharmaceutical companies against those who favored the repositioning of existing drugs. Our study explored perceptions of the association between drug novelty and effectiveness as well as perceptions of the role of the pharmaceutical industry in drug development. METHODS Data were collected in January 2021 from a quota sample of the French population aged 18-75years (n=1,000) during the second round of the "Health Literacy Survey 2019" (HLS19). RESULTS We tested the hypothesis that individuals with a high level of familiarity with the health care system and those with a high level of trust in institutions are more likely to agree that new drugs are more effective than old ones and that drug development should be driven by the pharmaceutical industry. A quarter (25%) of respondents agreed that new drugs are always more effective than old ones. Agreement with this statement was stronger among respondents with a high level of familiarity with the health care system (as measured by the navigational health literacy score, OR 3.34 [2.13-5.24]). Respondents with a low level of trust in pharmaceutical companies or politicians were two times less likely to agree that new drugs are always more effective than old ones (OR 0.63 [0.42-0.95] and OR 0.68 [0.49-0.94], respectively). A high level of trust in pharmaceutical companies was reported by 42% of respondents, and 43% agreed that drug development should be driven by the pharmaceutical industry. CONCLUSION Our study shows that the perceived effectiveness of innovative drugs is associated with familiarity with the health care system and trust in institutions.
Collapse
Affiliation(s)
- Émilien Schultz
- Université Paris Cité, IRD, Ceped, 75006 Paris, France,SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l’Information Médicale, CANBIOS team (équipe labellisée LIGUE 2019), Aix-Marseille Université, Inserm, IRD, 13009 Marseille, France,Corresponding. CEPED, 45, rue des Saints-Pères, 75006 Paris, France
| | - Léo Mignot
- University of Bordeaux, CNRS, CED, UMR 5116, 33600 Pessac, France,Sciences Po Bordeaux, CNRS, CED, UMR 5116, 33600 Pessac, France
| | - Jeremy K. Ward
- CERMES3, Inserm, CNRS, EHESS, Université de Paris Cité, 94801 Villejuif, France,VITROME, Aix-Marseille University, IRD, AP-HM, SSA, 13005 Marseille, France
| | - Daniela Boaventura Bomfim
- University of Bordeaux, CNRS, CED, UMR 5116, 33600 Pessac, France,SIRIC BRIO, CHU de Bordeaux, Institut Bergonié, Université of Bordeaux, Inserm, CNRS, 33000 Bordeaux, France
| | - Christian Chabannon
- Module Biothérapies du Centre d’Investigations Cliniques en Biothérapies, Inserm CBT-1409, Aix-Marseille Université, Institut Paoli-Calmettes comprehensive cancer center, 13005 Marseille, France
| | - Julien Mancini
- SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l’Information Médicale, CANBIOS team (équipe labellisée LIGUE 2019), Aix-Marseille Université, Inserm, IRD, 13009 Marseille, France,BioSTIC, AP–HM, Timone, 13005 Marseille, France
| |
Collapse
|
11
|
Zolezzi M, Paravattil B, El-Gaili T. Using motivational interviewing techniques to inform decision-making for COVID-19 vaccination. Int J Clin Pharm 2021; 43:1728-1734. [PMID: 34599721 PMCID: PMC8486954 DOI: 10.1007/s11096-021-01334-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2021] [Accepted: 09/18/2021] [Indexed: 11/29/2022]
Abstract
Motivational interviewing is a patient-centered communication style used to enhance a person’s internal motivation for attitudinal change by exploring and solving inherent ambivalences. In the face of rising COVID-19 vaccine hesitancy, pharmacists and other health care professionals may use motivational interviewing to enable individuals making informed decisions with regards to the COVID-19 vaccines. The purpose of this article is to integrate theory with practice by describing a scenario that illustrates how motivational interviewing skills and strategies can be used to reduce COVID-19 vaccine hesitancy.
Collapse
Affiliation(s)
- Monica Zolezzi
- College of Pharmacy, QU Health, Qatar University, Doha, Qatar.
| | | | | |
Collapse
|
12
|
Molimard M, Richard V, Cracowski JL. COVID-19: Pharmacology has kept the science ship running during the storm. Therapie 2021; 76:275-276. [PMID: 34119318 PMCID: PMC8161723 DOI: 10.1016/j.therap.2021.05.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Accepted: 05/20/2021] [Indexed: 11/02/2022]
Affiliation(s)
- Mathieu Molimard
- University Bordeaux, INSERM, BPH, U1219, Team Pharmacoepidemiology, 146, rue Leo Saignat, 33000 Bordeaux, France.
| | - Vincent Richard
- Normandy University, UniRouen, Inserm U1096 EnVI & Department of Pharmacology, 76000 Rouen, France
| | | |
Collapse
|